ADIS reported Internal Medicine Research & Non-Research Awards From 04/01/2017 to 09/30/2017
Proposal TitleADIS ID# Sponsor Dates Direct Cost Indirect Cost Total Cost
Burdorf, Adam F, CardioMEMS HF System Post Approval Study 20872 St. Jude Medical Company 08/01/17-07/31/20, $68,887, $17,131, $86,018
Chatzizisis, Ioannis S, Microscale Investigation of Mechanobiology of Atherosclerosis Using Novel Microfluidic Biochambers, Nebraska Research Initiative 07/01/17-06/30/17, $150,000,$150,000
Duan, Bin, Bio-inspired engineered pediatric valve regulates MSC differentiation and MSC-monocyte interaction 20390 American Heart Association – National07/01/17-06/30/18, $212,727, $18,273, $231,000
Lowes, Brian D, Dilated Cardiomyopathy (DCM) Research Project21023Ohio State University 01/01/17-04/30/17, $84,254, $42,549, $126,803
Porter, Thomas Richard, Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management1941, NuvOx Pharma, LLC, 04/01/17-03/31/18, $57,858, $29,218, $87,076
Windle, John Robert, Optimizing the Electronic Health Record for Cardiac Care16308 DHHS/AHRQ 09/01/17-08/31/18, $370,086, $116,718, $486,804
Zolty, Ronald, A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction, 20800, Amgen, Inc., 07/22/17-07/21/2, $192,576, $49,290, $241,866
Desouza, Cyrus Victor,GRADE [Glycemic Reduction Approaches for Diabetes: A Comparative Effectiveness Study] 15785 George Washington University, 08/01/16-07/31/17, $36,029, $12,608, $48,637
Desouza, Cyrus Victor, Midwestern Collaborative for Treating Obesity in Rural Primary Care, 18181 University of Kansas Medical Center Research Institute Inc, 01/01/17-12/31/17, $124,575, $49,830, $174,405
Desouza, Cyrus Victor, Vitamin D to prevent type 2 diabetes (D2d study) 15982Tufts University 06/01/17-05/31/18, $175,338, $81,318, $256,656
Desouza, Cyrus Victor, Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts withdiabeTes (PROMINENT) 20882, Kowa Pharmaceuticals America, Inc., 06/14/17-11/30/22, $610,385, $158,440, $768,825
Goldner, Whitney, Clinical Performance Evaluation of a New Thyroglobulin Assay in Subjects with Differentiated Thyroid Cancer (DTC) 20661 Roche Diagnostics Corp. 07/25/17-10/30/19, $106,037, $27,570, $133,607
Casey, Carol A, Altered Lipid Droplet Trafficking Role in Alcoholic Fatty Liver Disease 19689 DHHS/NIH/NIAAA 05/01/17-04/30/18, $465,950, $52,408, $518,358
Ouellette, Michel M, RAC1 GTPase in tumorigenesis and progression of pancreatic cancer 19286 DHHS/NIH/NCI 05/01/17-04/30/18, $224,099, $113,170, $337,269
Rasineni, Karuna, Pancreas-Adipose-Liver Axis: Role of Ghrelin and Insulin in Alcoholic Fatty Liver 19221 DHHS/NIH/NIAAA 05/01/17-04/30/18 ,$111,705, $8,936, $120,641
Ashford, Allison, Reducing Adverse Events Related to Opioids (RADEO) 21066 Society of Hospital Medicine 12/01/16-04/30/18, $4,762, $1,238, $6,000,
Hannan, Jeannine M, Engage Wellness Diabetes Program 20048 Douglas County Health Department 09/30/16-09/29/17, $1,000, $0, $1,000
Florescu, Diana Florentina, Phase II Multi-Center,Prospective, Randomized, Double-Blind Study of Nitazoxanide in Acute and Chronic Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients,19040Northwestern University-Chicago 07/01/16-06/30/21, $44,292, $22,367, $66,659
Florescu, Diana Florentina,A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-Fumigatus Species 20496, Astellas Pharma Global Development, Inc., 04/13/17-04/12/21, $7,066, $1,057, $8,123
Florescu, Diana Florentina,Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles 20494, Astellas Pharma Global Development, Inc., 05/01/17-04/30/21, $36,068, $8,598, $44,666
Hewlett, Angela L, An Expanded Access Treatment Protocol for ZMapp for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure, 21037, Mapp Biopharmaceutical, Inc., 05/31/17-06/30/19, $33,756, $17,047, $50,803
Kalil, Andre C, Professional Services Agreement: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy, 16877Rhode Island Hospital03/01/17-07/31/18, $14,348, $3,730, $18,078
Rupp, Mark E, Infection Control Assessment and Promotion 19296NE DHHS 04/20/15-03/31/18, $127,916, $0, $127,916
Rupp, Mark E, Nebraska Antimicrobial Stewardship Assessment and Promotion (Nebraska Asap) Subaward 21053 NE DHHS 10/01/16-07/31/17, $426,622, $14,241, $440,863
Rupp, Mark E,Retrospective Epidemiological Study to Derive Certain Data Related to False Postivie Results from Blood Culture Contamination 20984, Magnolia Medical Technologies, Ltd., 05/15/17-03/14/18, $31,655, $7,970, $39,625
Swindells, Susan, AIDS Drug Assistance Program [ADAP] Ryan White Title II Program (Part B) 1285 NE DHHS 04/01/16-03/31/17, $1,167,248, $0, $1,167,248
Swindells, Susan, A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI-based…, 20165 GlaxoSmithKline 12/28/16-12/27/17 $263,992, $92,753, $356,745
Swindells, Susan, Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) R24 AI118397-02 20963 Johns Hopkins University02/01/17-04/30/17, $26,050, $13,156, $39,206
Swindells, Susan, AIDS Drug Assistance Program [ADAP] Ryan White Title II Program (Part B) 21175 NE DHHS 04/01/17-03/31/18, $3,547,668, $0, $3,547,668
Swindells, Susan, Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) R24 AI118397-02, 20963 Johns Hopkins University05/01/17-04/30/18, $50,222, $25,362, $75,584
Holstein, Sarah A, A phase 1, multicenter, open-label, safety study of human cord blood derived, culture-expanded, natural killer cell (PNK-007) infusion following autologous stem cell transplant for multiple myeloma, 20583Celgene Corporation 02/28/17-02/27/19 $74,713, $18,645, $93,358
Holstein, Sarah A,Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose…, 20799, JANSSEN R&D, LLC, 04/13/17-04/12/21,$420,056, $108,955, $529,011
Krishnamurthy, Jairam,A phase II clinical trial assessing the safety of an alternative dosing schedule of palbociclib in metastatic hormone receptor positive breast cancer21117Washington University07/05/17-07/04/19, $114,477, $28,984, $143,461
Lunning, Matthew A, Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN Rider 1302), 19001 National Marrow Donor Program 03/01/16-02/28/18, $32,048, $8,973, $41,021
Shonka, Nicole Annette, A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification, 20178, AbbVie, Inc., 12/05/16-12/04/18, $1,018,459, $264,019, $1,282,478
Tandra, Pavankumar, A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastic Hormone Receptor Positive Breast Cancer20869Big Ten Cancer Research Consortium 08/14/17-08/13/19, $58,452, $14,418, $72,870
Vose, Julie M, Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma 14822 Onyx Pharmaceuticals 06/20/17-06/20/18, $29,876, $7,768, $37,644
Bailey, Kristina Lynn, Mucociliary clearance in aging 19544 DHHS/NIH/NIA 05/01/17-04/30/18, $184,500, $93,172, $277,672
Dickinson, John David, Role of Autophagy and the ATG16L1 Gene Variant in Cystic Fibrosis 19528 Cystic Fibrosis Foundation 04/01/17-03/31/18, $49,093, $3,927, $53,020
Harrington, John J, Tailored treatment to enhance risk perception in sleep apnea – subcontract with National Jewish Health 18868 National Jewish Research 04/01/17-03/31/18, $14,615, $7,380, $21,995
Murphy, P. James, A CF C3N Care Model of the Future: Proposal for Piloting a Learning Health System20461Cincinnati Children’s Hospital Medical Center 01/01/17-12/31/17, $30,000, $2,400, $32,400
Murphy, P. James, CFF Center Adult Program 17416 Cystic Fibrosis Foundation07/01/17-06/30/18, $102,120,$0, $102,120
Rennard, Stephen Israel, Defining the Role of Early Pulmonary Vascular Disease in COPD 19225 University of Iowa 04/01/17-03/31/18, $6,718, $3,393, $10,111
Thompson, Austin Bassett, A phase 3, placebo controlled, double-blind, randomized, clinical study to determine efficacy, safety and tolerability of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial hypertension (PAH): INOvation-1, 20344 Bellerophon Pulse Technologies, LLC, 06/07/17-06/06/19, $56,434, $13,893, $70,327
Warren, Kristi J, Sex differences in lung innate lymphoid cells 20638 American Lung Association – National, 07/01/17-06/30/18, $40,000, $0, $40,000
Mikuls, Ted Richard, The Safety and Effectiveness of the VaricElla zosteR VaccinE (VERVE) in Anti-TNF Users 20022University of Alabama – Birmingham03/17/17-03/16/18, $14,000, $0, $14,000
Mikuls, Ted Richard, Summer Undergraduate Alcohol Research Program 19990 DHHS/NIH/NIAAA 04/10/17-03/31/18, $59,483, $2,743, $62,226
Mailliard, Mark Edward, A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis, 21057, AbbVie, Inc., 09/01/17-08/31/19, $70,756, $17,617, $88,373
Rupp, Mark E, A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients with Staphylococcus…,20646, ContraFect Corporation, 10/01/17-03/31/19, $74,429, $18,572, $93,001
Swindells, Susan, Ryan White Part D Program for Coordinated HIV Services & Access to Research for Women, Infants, Childrens, and Youth (WICY), 16184DHHS/HRSA, 08/01/17-07/31/18, $368,359,$0, $368,359
Vose, Julie M, A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL), 21176, Kite Pharma, Inc., 09/06/17-08/01/19, $185,451, $47,437, $232,888
Dickinson, John David, Autophagy regulates airway epithelial cell mucin secretion, 19322, DHHS/NIH/NHLBI, 09/01/17-08/31/18, $148,000, $11,840, $159,840
Feely, Michael Gray, A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathis Inflammatory Myopathy (IIM), 20820, Bristol-Myers Squibb Company, 06/13/17-06/29/19, $57,890, $14,791, $72,681